Overview

A Phase 2 Study Comparing TAS-102 Versus Topotecan or Amrubicin to Treat Small Cell Lung Cancer Following Platinum-Based Chemotherapy

Status:
Terminated

Trial end date:
2014-06-01

Target enrollment:

Participant gender:

Summary

The purpose of this trial is to compare the effects of TAS-102 with either amrubicin or topotecan (drugs used in Small Cell Lung Cancer) on lung cancer to find out the effects on survival, how much time may pass without disease progression, and the safety of TAS-102.

Phase:

Phase 2

Details

Lead Sponsor:

Taiho Oncology, Inc.

Collaborator:

Taiho Pharmaceutical Co., Ltd.

Treatments:

Amrubicin
Topotecan
Trifluridine